chartexchange

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

GlobeNewswire Inc. | Nov 5, 2026 4:30 PM EST

First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027

Read original article